Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diageo plc (DEO) vs Revvity Inc (RVTY) Price & Performance

Diageo plcTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Diageo plc vs Revvity Inc — how do they compare? Diageo plc trades at $93.48 (market cap $53.05B), while Revvity Inc trades at $115.96 (market cap $12.91B). The key difference: Diageo plc is far larger — about 4.1× Revvity Inc's market cap, and Diageo plc pays the higher dividend (3.5%). Which is the better fit depends on your goals.

DEORVTY
Market Cap
$53.05B$12.91B
Sector
TechnologyTechnology
52-Week High
$115.33$117.75
52-Week Low
$72.47$82.26
Enterprise Value
$72.54B$15.23B
Dividend Yield
3.5%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diageo plc

Diageo (DEO) trades at $93.61, down 3.6% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. A new $1 billion savings plan and focus on spirits and Guinness aim to drive a turnaround, with cash flow from operations strong at $4.4 billion in 2026.

The outlook is cautiously optimistic, with analyst consensus leaning buy (49%) amid execution of the cost-cutting strategy. Risks include North America weakness and competitive pressures, but valuation metrics like P/E of 30.5 reflect growth expectations. The stock offers potential for recovery if management delivers on efficiency gains and market share stabilization.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Diageo plc

Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.

Read more on DEO

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY